GSA Capital Partners LLP Makes New Investment in TransMedics Group, Inc. $TMDX

GSA Capital Partners LLP purchased a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 5,981 shares of the company’s stock, valued at approximately $671,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Guidance Capital Inc. bought a new stake in shares of TransMedics Group in the 3rd quarter valued at $212,000. Vanguard Group Inc. grew its holdings in TransMedics Group by 0.3% in the third quarter. Vanguard Group Inc. now owns 3,605,607 shares of the company’s stock worth $404,549,000 after purchasing an additional 9,650 shares during the period. Bastion Asset Management Inc. bought a new stake in TransMedics Group in the third quarter valued at $5,133,000. State of New Jersey Common Pension Fund D raised its holdings in shares of TransMedics Group by 17.2% during the third quarter. State of New Jersey Common Pension Fund D now owns 17,903 shares of the company’s stock valued at $2,009,000 after purchasing an additional 2,633 shares during the period. Finally, PNC Financial Services Group Inc. raised its holdings in shares of TransMedics Group by 19.9% during the third quarter. PNC Financial Services Group Inc. now owns 3,639 shares of the company’s stock valued at $408,000 after purchasing an additional 604 shares during the period. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Stock Up 1.0%

Shares of NASDAQ:TMDX opened at $134.25 on Monday. The stock has a market cap of $4.59 billion, a price-to-earnings ratio of 54.35 and a beta of 2.06. The company has a quick ratio of 7.13, a current ratio of 7.69 and a debt-to-equity ratio of 1.43. TransMedics Group, Inc. has a 12-month low of $62.07 and a 12-month high of $156.00. The business’s 50 day moving average is $132.50 and its 200 day moving average is $125.92.

Analyst Upgrades and Downgrades

TMDX has been the subject of several research reports. Wall Street Zen upgraded TransMedics Group from a “hold” rating to a “buy” rating in a research note on Saturday, February 14th. Needham & Company LLC raised their price objective on TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Piper Sandler restated an “overweight” rating on shares of TransMedics Group in a report on Monday, December 22nd. Morgan Stanley increased their target price on TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 2nd. Finally, Canaccord Genuity Group increased their target price on TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Six investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $144.25.

Insiders Place Their Bets

In related news, CFO Gerardo Hernandez sold 920 shares of the business’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $139.62, for a total transaction of $128,450.40. Following the transaction, the chief financial officer directly owned 15,064 shares in the company, valued at approximately $2,103,235.68. The trade was a 5.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Anil P. Ranganath sold 3,000 shares of the company’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total transaction of $435,660.00. Following the completion of the sale, the insider directly owned 13,955 shares of the company’s stock, valued at $2,026,545.10. The trade was a 17.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 8,920 shares of company stock valued at $1,257,310 in the last three months. 7.00% of the stock is currently owned by insiders.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.